ZEDOTT DT

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only Abbreviated Prescribing information for ZEDOTT DT 10/30 [Racecadotril Dispersible Tablets 10mg and 30mg] [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: In peripheral tissues, orally administered racecadotril is rapidly hydrolysed to the more potent enkephalinase inhibitor thiorphan. Within these tissues, membrane-bound enkephalinase enzymes degrade endogenous opioids (enkephalins). Inhibition of enkephalinase by thiorphan increases the availability of opioids, which activate delta opioids receptors in the gastrointestinal tract. This in turn leads to a reduction in cAMP mucosal levels, resulting in a reduction in the secretion of water and electrolytes into the intestinal lumen.

INDICATION: For the treatment of acute diarrhoea in children.

DOSAGE AND ADMINISTRATION: The recommended dose of racecadotril in children is 1.5mg/kg every eight hourly. Disperse the tablets in a teaspoon full of water before administration.

CONTRAINDICATION: contraindicated in patients with known hypersensitivity to the ingredients of the formulation.

WARNINGS & PRECAUTIONS: Caution should be exercised in patients with history of kidney impairment, intestinal disorders, during pregnancy and breastfeeding.

DRUG INTERACTIONS: No significant drug interactions with antibiotics and oral rehydration salt (ORS).

ADVERSE REACTIONS: Dizziness, malaise, headache, hypokalemia, constipation, abdominal distension and vomiting.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD. Torrent House, Off Ashram Road, Ahmedabad-380 009, INDIA

IN/ZEDOTT DT/Feb-2015/01/AbPI

(Additional information is available on request)